Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes
Authors:
Open Access
- 4 March 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (3) , e242859
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by inattention, hyperactivity-impulsivity, or both.1 The prevalence of ADHD has been estimated to be approximately 5%.2 Although symptoms start in childhood, they often persist into adulthood, with an estimated ADHD prevalence of 2.5% among adults.3 ADHD often co-occurs with other psychiatric disorders, such as communication disorders, intellectual and learning disabilities, autism spectrum disorders, mood disorders, anxiety disorders, and substance use disorders.1 Heterogeneity in symptom profiles and psychiatric comorbidities are challenges in the treatment of ADHD in children, adolescents, and adults.Keywords
This publication has 30 references indexed in Scilit:
- Comparative Effectiveness of Pharmacotherapies for the Risk of Attempted or Completed Suicide Among Persons With Borderline Personality DisorderJAMA Network Open, 2023
- Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 PatientsJAMA Psychiatry, 2022
- Association Between Pharmacological Treatment of Attention-Deficit/Hyperactivity Disorder and Long-term Unemployment Among Working-Age Individuals in SwedenJAMA Network Open, 2022
- Association of Psychiatric Comorbidity With the Risk of Premature Death Among Children and Adults With Attention-Deficit/Hyperactivity DisorderJAMA Psychiatry, 2019
- Six-year outcome in subjects diagnosed with attention-deficit/hyperactivity disorder as adultsEuropean Archives of Psychiatry and Clinical Neuroscience, 2017
- Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle CrashesJAMA Psychiatry, 2017
- Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorderEuropean Child & Adolescent Psychiatry, 2017
- Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and AtomoxetineCNS Drugs, 2017
- Medication for Attention-Deficit/Hyperactivity Disorder and Risk for Depression: A Nationwide Longitudinal Cohort StudyBiological Psychiatry, 2016
- The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescentsInternational Archives of Occupational and Environmental Health, 2012